Should we? These experts answer that question in Part 2 of our Talking Techniques podcast with BioTechniques:
- David Dimmock
Senior Medical Director at Rady Children’s Institute of Genomic Medicine - Christine Stanley
Chief Director of Clinical Genomics at Variantyx - Take Ogawa
Chief Commercial Officer at Psomagen
This content was produced in association with Biotechniques, Variantyx, and Rady Children’s Institute of Genomic Medicine.
Contents:
- Introductions: 00:00-02:20
- Gauging public perceptions of routine WGS 02:20-05:40
- The role of industry in improving WGS accessibility and capabilities: 05:40-07:35
- The appropriate use of pre-symptomatic and predictive risk findings: 08:00-11:15
- Debating the discovery of untreatable diseases: 11:15-12:45
- The impact of data biases in gene sequencing and the lack of gene references for different populations: 12:45-14:45
- The impact of religion and lifestyle on ethical considerations in the use of WGS data: 14:45-16:00
- Dealing with unintended findings or results that impact relatives: 16:00-16:45
- The value of WGS in pharmacogenomic variant findings and challenging the ACMG59 list: 16:45-19:20
- Striking the balance between fully utilizing WGS for all potential findings and ensuring maximum participation for all groups: 19:20-22:45
- Filtering data to avoid exclusion: 22:45-24:10
- Who owns WGS data? 24:10-25:15
- Consent conversations: 25:15-26:30
- Final comments: 26:30-27:15
RELATED CONTENT:
-
🎥 VIDEO
-
🎙 PODCAST
Talking Techniques: Episode 1
Whole-Genome Sequencing: Navigating the ‘Diagnostic Odyssey’ in rare disease research -
📊 INFOGRAPHIC
-
📊 INFOGRAPHIC
